Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Dearden C . Disease-specific complications of chronic lymphocytic leukemia. Hematology 2008; 2008: 450–456.

    Article  Google Scholar 

  2. Diehl LF, Ketchum LH . Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97.

    CAS  PubMed  Google Scholar 

  3. Cines DB, Bussel JB, Liebman HA, Luning Prak ET . The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511–6521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV . Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1–10.

    CAS  PubMed  Google Scholar 

  5. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887–895.

    Article  CAS  PubMed  Google Scholar 

  6. Nurden AT, Viallard J-F, Nurden P . New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009; 373: 1562–1569.

    Article  CAS  PubMed  Google Scholar 

  7. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641–648.

    Article  CAS  PubMed  Google Scholar 

  8. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371: 395–403.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to W G Wierda.

Ethics declarations

Competing interests

Michael J Keating is a consultant for GlaxcoSmithKline. William G Wierda received research funding from and has served as a consultant for GlaxcoSmithKline. Stefan Koehrer has no conflict of interest to disclose.

Additional information

Author contributions

Stefan Koehrer reviewed, analyzed, summarized patient data, wrote paper and approved the final version of the paper. Michael J Keating was the treating physician for patients and approved the final version of the paper. William G Wierda was the treating physician for patients, and reviewed, analyzed, summarized patient data, wrote paper and approved the final version of the paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koehrer, S., Keating, M. & Wierda, W. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 24, 1096–1098 (2010). https://doi.org/10.1038/leu.2010.45

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.45

This article is cited by

Search

Quick links